Navigation Links
Teva Applauds Historic Biotech Competition Legislation
Date:3/11/2009

Bi-Partisan Waxman-Deal Bill will increase access and savings for American consumers

NORTH WALES, Pa., March 11 /PRNewswire-USNewswire/ -- Teva Pharmaceuticals USA, the leading generic pharmaceutical company, today applauded the introduction of a landmark, bi-partisan bill that would bring safe and affordable generic biologics to all Americans. Energy and Commerce Chairman Henry Waxman and Ranking Health Subcommittee Republican Nathan Deal, together with Representatives Frank Pallone and Jo Ann Emerson, introduced the Promoting Innovation and Access to Life Saving Medicines Act in the House of Representatives today following years of debate over the establishment of an FDA approval pathway for biogenerics.

"Representatives Waxman, Deal, Pallone and Emerson have reached a remarkable milestone with this bill; one that can have an enormous positive impact on our biopharmaceutical market," said William Marth, President and CEO of Teva North America. "But more importantly, it's a law that can provide a vast benefit for all Americans and save billions at the same time. Teva looks forward to working with Congress, the White House and stakeholders nationwide to see their work become a reality," Marth concluded.

The average daily cost of a biologic product is approximately 22 times greater than a traditional drug. The potential savings from biogenerics are huge. A 2008 economic study found that a U.S. biogenerics market would both promote competition and generate cost savings of just over $100 billion over the next 10 years. Large employers, pharmacy benefits managers, health plans, consumer groups, generic drug manufactures and others have been waiting for legislation that will establish a sound scientific regulatory pathway and properly balance the need for patient access with incentives for continued innovation.

Just last month, Teva launched the "Year of Affordable Healthcare," a nationwide campaign to recognize the important role that generic drugs play and commemorate the 25th anniversary of the landmark Waxman-Hatch Act which created the modern generic drugs industry and has resulted in billions of dollars of savings.

About Teva

Teva USA is a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., one of the largest generic pharmaceutical companies in the world and among the top 20 pharmaceutical companies. For more information, please visit www.tevausa.com or www.tevadc.com.


'/>"/>
SOURCE Teva Pharmaceuticals USA
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. International Society for Stem Cell Research Applauds Outcome of Proposal 2 Advancing Stem Cell Research
2. Solos Endoscopy, Inc. Applauds American College of Surgeons Review of Advanced Breast Cancer Detection at 94th Annual Clinical Congress
3. Air Transport Association Applauds House of Representatives on Decision to Withhold Biometric Collection Funding
4. ISMPP Applauds AAMC Clarification on Ghostwriting Versus Transparent Writing Collaboration in Scientific Publications
5. Orchid Cellmark Applauds Expansion of Federal Forensic DNA Identity Testing to Include All Arrestees
6. Childhood Influenza Immunization Coalition Applauds Expanded Influenza Vaccine Recommendation for Children
7. Novo Nordisk Applauds Adoption of World Diabetes Day Resolutions by U.S. Congress
8. FRC Applauds New Ballot Initiative for Cures Without Cloning
9. Monsantos Historic R&D Investment has Contributed to Mid-20s Gross Profit Growth for Its Seeds and Genomics Segment
10. Historic Seed Delivery Made in Illinois for First New Soybean Varieties With the Greater Yield Potential of Roundup Ready 2 Yield(TM)
11. African Ancestry, Educators, Identity Experts Launch DNA Education Project during Historic Black History Month; 7th Graders Score High on Ultimate Self Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... 11, 2016  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today ... 31, 2015. --> --> ... loss of $29.3 million, or $0.34 loss per share, compared to ... for the same period in 2014. For the year ended December ... or $1.05 loss per share, as compared to a net loss ...
(Date:2/11/2016)... NEW YORK , Feb. 11, 2016  Bioethics International, ... how medicines are researched, developed, marketed and made accessible to ... BMJ Open had named the publication of the ... for 2015. The publication is also featured as one of ... published in the last year that are most frequently read. ...
(Date:2/11/2016)... NY (PRWEB) , ... February ... ... a business-to-business publication dedicated to delivering cutting-edge information focused on the development ... Life Sciences to become a premier sponsor of the 2016 BioProcess International ...
(Date:2/11/2016)... 11, 2016   BioInformant announces the February ... Research Products, Opportunities, Tools, and Technologies – Market Size, ... The first and ... cell industry, BioInformant has more than a decade of ... market, by stem cell type. This powerful 175 page ...
Breaking Biology Technology:
(Date:2/10/2016)... , February 10, 2016 ... According to 2016 iris recognition market ... iris recognition is more widely accepted for ... with both fingerprint and iris recognition technology ... user to avoid purchasing two individual biometrics ...
(Date:2/8/2016)... 2016 Worldcore is ... innovation for clients, comfort and unbeatable security, with ... --> Worldcore is the first EU-regulated ... comfort and unbeatable security, with a Voice Biometrics ... Worldcore is the first EU-regulated global payment ...
(Date:2/3/2016)... --> --> Fourth quarter ... up 1,187% compared with fourth quarter of 2014. Gross margin ... (loss: 30.0). Earnings per share increased to SEK 6.39 (loss: ... (neg: 74.7). , --> --> ... 2,900.5 M (233.6), up 1,142% compared with 2014. Gross margin ...
Breaking Biology News(10 mins):